Leucémie myéloïde chronique et inhibiteurs de tyrosine kinase
- 1 September 2001
- journal article
- research article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 22 (9) , 894-899
- https://doi.org/10.1016/s0248-8663(01)00441-6
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase InhibitorJNCI Journal of the National Cancer Institute, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Antisense oligomers in chronic myeloid leukaemiaThe Lancet, 1993
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990